G. Roubaud Et Al. , "Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound," ESMO Virtual Congress , vol.31, ELECTR NETWORK, 2020
Roubaud, G. Et Al. 2020. Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound. ESMO Virtual Congress , (ELECTR NETWORK).
Roubaud, G., ÖZGÜROĞLU, M., Penel, N., Matsubara, N., Mehra, N., Kolinsky, M. P., ... Procopio, G.(2020). Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound . ESMO Virtual Congress, ELECTR NETWORK
Roubaud, G. Et Al. "Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound," ESMO Virtual Congress, ELECTR NETWORK, 2020
Roubaud, G. Et Al. "Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound." ESMO Virtual Congress , ELECTR NETWORK, 2020
Roubaud, G. Et Al. (2020) . "Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound." ESMO Virtual Congress , ELECTR NETWORK.
@conferencepaper{conferencepaper, author={G. Roubaud Et Al. }, title={Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound}, congress name={ESMO Virtual Congress}, city={}, country={ELECTR NETWORK}, year={2020}}